Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gynecologic Oncology

• Publication date

  2014-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2014.03.007PMID 24631446PMCID PMC4347923
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.

  2013cited by this paper
• Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.

  2012influential reference
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012influential reference
• Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

  2012cited by this paper
• Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma

  2012influential reference
• Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination.

  2011cited by this paper
• The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells

  2011influential reference
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Chemical Phylogenetics of Histone Deacetylases

  2010cited by this paper
• Hdac3 is essential for the maintenance of chromatin structure and genome stability.

  2010cited by this paper
• Residual γH2AX foci as an indication of lethal DNA lesions

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• DNA fingerprinting of the NCI-60 cell line panel

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control.

  2008cited by this paper
• A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

  2008cited by this paper
• HDAC4 promotes growth of colon cancer cells via repression of p21.

  2008cited by this paper
• HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

  2007influential reference
• Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation

  2007cited by this paper
• Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

  2007cited by this paper
• FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

  2007cited by this paper
• Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy

  2007cited by this paper
• On testing the significance of sets of genes

  2006cited by this paper
• Non-hydroxamate histone deacetylase inhibitors.

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy.

  2005cited by this paper
• The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Spontaneous Homologous Recombination Is Induced by Collapsed Replication Forks That Are Caused by Endogenous DNA Single-Strand Breaks

  2005cited by this paper
• Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

  2004cited by this paper
• TR3/Nur77 in colon cancer cell apoptosis.

  2003cited by this paper
• DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.

  2001cited by this paper
• Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines

  2000cited by this paper
• Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.

  1998cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Chinese Anti鄄 Cancer a Ssociation

  year unknowncited by this paper

• Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

  2026cites this paper
• RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer

  2025cites this paper
• Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model

  2025cites this paper
• Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group

  2024cites this paper
• Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment

  2024cites this paper
• Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy

  2024cites this paper
• Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations

  2024cites this paper
• Patents on PARP-1 Inhibitors for the Management of Cancer from 2017-2023.

  2024cites this paper
• Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements.

  2023cites this paper
• KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer

  2023cites this paper
• Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824

  2023cites this paper
• Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer

  2023cites this paper
• Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers

  2022cites this paper
• Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment.

  2022cites this paper
• DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities

  2022cites this paper
• Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progression in vivo and in vitro

  2022cites this paper
• Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2α dephosphorylation and its phosphomimetic S51D variant

  2022cites this paper
• Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress in vitro.

  2022cites this paper
• Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma

  2022cites this paper
• Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells

  2022cites this paper
• Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.

  2022cites this paper
• Dual-target inhibitors based on PARP1: new trend in the development of anticancer research.

  2022cites this paper
• Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition

  2022cites this paper
• Overexpression of CAPG Is Associated with Poor Prognosis and Immunosuppressive Cell Infiltration in Ovarian Cancer

  2022cites this paper
• Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.

  2021cites this paper
• Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer

  2021cites this paper
• Clinical utility of solid tumor epigenetics

  2021cites this paper
• Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair

  2021cites this paper
• Ovarian cancer: epigenetics, drug resistance, and progression

  2021cites this paper
• Understanding and overcoming resistance to PARP inhibitors in cancer therapy

  2021cites this paper
• Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance

  2021cites this paper
• Emerging roles of non-histone protein crotonylation in biomedicine

  2021cites this paper
• Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.

  2021cites this paper
• In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging

  2021cites this paper
• Pharmacological methods to transcriptionally modulate double-strand break DNA repair.

  2020cites this paper
• Role of Rad51 and DNA repair in cancer: A molecular perspective.

  2020cites this paper
• Pediatric glioblastoma - unlike normal cells - are sensitive to the combination of vorinostat and olaparib and to its downstream effector - phosphorylated eIF2α

  2020cites this paper
• Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics

  2020cites this paper
• Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs

  2020cites this paper
• Resolving DNA Damage: Epigenetic Regulation of DNA Repair

  2020cites this paper
• Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas

  2020cites this paper
• Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes

  2020influential citation
• Small-molecule drug repurposing to target DNA damage repair and response pathways.

  2020cites this paper
• Mild antagonistic effect of Valproic acid in combination with AZD2461 in MCF-7 breast cancer cells

  2019cites this paper
• PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

  2019cites this paper
• Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer

  2019cites this paper
• Recent study of dual HDAC/PARP inhibitor for the treatment of tumor.

  2019cites this paper
• Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid

  2019cites this paper
• PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.

  2019cites this paper
• Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

  2019cites this paper
• Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer

  2019cites this paper
• Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling

  2018cites this paper
• Novel Poly (ADP-Ribose) Polymerase Inhibitor AZD2461 Combined with Valproic Acid Exerts Mild Antagonistic Effects in Hela Cells

  2018cites this paper
• MutT homolog 1 counteracts the effect of anti-neoplastic treatments in adult and pediatric glioblastoma cells

  2018cites this paper
• The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

  2018influential citation
• Interplay of Histone Marks with Serine ADP-Ribosylation

  2018cites this paper
• Mechanisms Of RAD51D-Dependent Repair Of DNA And Telomere Damage Induced By Interstrand Crosslinking Agents And Thiopurines

  2018cites this paper
• 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors

  2018cites this paper
• Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.

  2018cites this paper
• The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.

  2018cites this paper
• Homologous Recombination and BRCA Genes in Ovarian Cancer: Clinical Perspective of Novel Therapeutics

  2017cites this paper
• Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation

  2017cites this paper
• Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

  2017cites this paper
• Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells

  2017cites this paper
• Chapter 3 – Epigenetics

  2017cites this paper
• Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

  2017cites this paper
• Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine

  2017cites this paper
• Cancer de l’ovaire et inhibiteur de PARP : parcours des patientes en génétique oncologique

  2017cites this paper
• Microhomology-mediated end joining: Good, bad and ugly.

  2017cites this paper
• Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.

  2017cites this paper
• Interstrand Crosslink Repair as a Target for HDAC Inhibition.

  2017cites this paper
• PARP inhibitors as antitumor agents: a patent update (2013-2015)

  2017cites this paper
• Ultradeep Lysine Crotonylome Reveals the Crotonylation Enhancement on Both Histones and Nonhistone Proteins by SAHA Treatment.

  2017cites this paper
• Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.

  2016cites this paper
• PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.

  2016cites this paper
• Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.

  2016cites this paper
• HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.

  2016cites this paper
• Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma

  2016cites this paper
• What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

  2016cites this paper
• Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells

  2016cites this paper
• Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines

  2016cites this paper
• Olaparib for the treatment of ovarian cancer.

  2016cites this paper
• RNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrity.

  2016cites this paper
• Predicting and Monitoring Responses to Epigenetic Drugs

  2016cites this paper
• Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.

  2016cites this paper
• Histone Deacetylase Inhibitors in Medical Therapeutics

  2016cites this paper
• A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells

  2016cites this paper
• Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

  2016cites this paper
• Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.

  2016cites this paper
• Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.

  2016cites this paper
• Therapeutic Strategies against Cyclin E1 Amplified Ovarian Cancers

  2016cites this paper
• Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

  2015cites this paper
• Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line

  2015cites this paper
• Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells

  2015cites this paper
• YU 238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-De fi cient Tumors

  2015cites this paper
• Olaparib: First Global Approval

  2015cites this paper
• Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer

  2015cites this paper
• PARP inhibitors: the journey from research hypothesis to clinical approval.

  2015cites this paper
• Histone deacetylase inhibitors in hematological malignancies and solid tumors

  2015cites this paper
• YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors

  2015cites this paper